摘要:
The proposed process for producing n-butyraldehyde and/or n-butanol involves the following steps: (a) 1,3-butadiene is allowed to react with an amine of formula (I) R1R2NH, in which the groups independently of one another represent hydrogen, optionally substituted aliphatic or cyclo-aliphatic groups, or aryl or aralkyl groups, or are connected to a bridging unit which can contain heteroatoms, at high temperature and pressure and in the presence of a compound of a group VIIIb element, in the presence of an alkali metal amide, or in the presence of a basic metal oxide, to form a mixture of addition compounds of formula (II) and (III); (b) addition compound (III) is isomerised to addition compound (II); (c) addition compound (II) is isomerised in the presence of a homogeneous or heterogeneous transition metal catalyst in liquid phase or in the presence of a heterogeneous catalyst containing transition metal in the gas phase to produce enamine of formula (IV); and (d) the enamine (IV) is converted, by reaction with hydrogen and water, or water, in the presence of a homogeneous or heterogeneous transition metal catalyst in liquid phase, in the presence of a heterogenous catalyst containing transition metal in the gas phase, in the presence of an acid or in the presence of one of the above mentioned catalysts and of an acid, to n-butyraldehyde and/or n-butanol, the amine (I) being released and the released amine (I) being led back into sub-reaction (a).
摘要:
This invention relates to hexa- and octahydrobenzo[f]quinolin-3-ones, pharmaceutical formulations containing those compounds and methods of their use as steroid 5α reductase inhibitors.
摘要:
A novel series of polycyclic amine derivatives, of formula I methods of making the compounds, novel intermediates, compositions containing them, and pharmaceutical compositions useful in the treatment and prevention of cerebrovascular disorders and useful as anesthetics or analgesics.
摘要:
A process for producing a chroman compound of the formula, or an optically active compound thereof
wherein R 2 , R 3 , and R 4 are each a hydrogen atom or a C 1 -C 4 alkyl group, which comprises reacting a compound of the formula, or an optically active compound thereof wherein A is an aryl group and Rs is a C 1 -C 4 alkyl group, with a compound of the formula,
wherein R 1 is a C 1 -C 3 alkyl group, X is a halogen atom and Rz, R 3 and R 4 are as defined above, to obtain a compound of the formula, or an optically active compound thereof wherein A, R 1 , R 2 , R 3 and R 4 are as defined above, reacting the resulting compound with methylmagnesium halide and then hydrolyzing to obtain a compound of the formula, or an optically active compound wherein R 1 , R 2 , R 3 and R 4 are as defined above, reducing the resulting compound to obtain a compound of the formula, or an optically active compound thereof wherein R 1 , R 2 , R 3 and R 4 are as defined above, and then oxidizing the resulting compound to obtain a compound of the formula, or an optically active compound thereof wherein R 2 , R 3 and R 4 are as defined above, followed by reduction.
The chroman compounds of this invention are an intermediate for the synthesis of tocopherols, particularly a-tocopherol.
摘要:
An optically active or racemic a-hydroxyaldehyde of formula and a compound having a benzyloxy group in place of its hydroxy group, wherein R, represents a C 6 -C 14 aryl group, C 1 -C 10 alkyl group, C 3 -C 10 alkenyl group, C 2 -C 10 alkynyl group, C 7 -C 14 aralkyl group, or a group containing a functional group in the organic portion of said groups, and R 2 represents a C 1 -C 10 alkyl group, C 1 -C 10 alkenyl group, C 2 -C 10 alkynyl group, C 7 -C 14 aralkyl group, C 6 -C 14 aryl group or a group containing a functional group in the organic portion of these groups, R, and R 2 being different groups, is an important intermediate for preparation of pharmaceuticals and agricultural chemicals.
摘要:
ABSTRACT The compounds of formula (I): where Ar is an aromatic ring and Ra, Rb, are as defined in the description, are useful in therapy as drugs for the treatment of diseases mediated by infiltrations of neutrophils induced by IL-8, such as psoriasis, rheumatoid arthritis, ulcerative cholitis and for the treatment of damages caused by ischemia and reperfusion.